INCYTE
Highly Engaged Employees
Manufacturing · Delaware, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1801 Augustine Cut Off, Wilmington, Dela...Phone Number
(302) 498-6700Website
www.incyte.comRevenue
$5.4 BillionStock Symbol
INCYIndustry
About INCYTE
INCYTE Org Chart
Is INCYTE your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when INCYTE launches new products
Funding: Get notified immidiatlly once INCYTE has new funding data
INCYTE, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on INCYTE recently announced quarterly report
Check if INCYTE has recently received funding, and reach out quickly before it becomes old news!
Click to see if INCYTE had a recent Job posting/layoffs
Check out if INCYTE is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at INCYTE
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to INCYTE
Compare insights from companies similar to INCYTE, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
INCYTE is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
INCYTE is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about INCYTE.
INCYTE Tech Stack
A closer look at the technologies used by INCYTE
Most Recent Scoops
INCYTE News & Media
Incyte pays Genesis $80M to expand AI-fueled drug discovery pact - Fierce Biotech
Incyte is paying Genesis $80 | Incyte is paying Genesis $80 million upfront to expand use of its partner’s AI platform across a broader range of targets, continuing the biotech’s rapid embrace of AI in drug discovery and development.Incyte CMO awarded 44,124 performance shares | INCY Insider Trading - Stock Titan
Incyte CMO Steven H. Stein earned 44,124 performance-based shares after goals were met; total 78,327 unvested RSUs and performance shares now reported.Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Incyte Corporation (INCY) RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:30 AM EDTCompany ParticipantsSteven Stein - Executive VP,...Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, late-stage pipeline activity and potential launches across oncology and immunology. Speaking at the
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INCYTE
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome... Read More



